Humacyte
Stock Forecast, Prediction & Price Target
Humacyte (HUMA) stock Price Target by analysts
$8
Potential upside: 399.87%
Humacyte price prediction
What is Humacyte stock analysts` prediction?
Humacyte stock forecast: Based on 2 Wall Street analysts` predicted price targets for Humacyte in the last 3 months, the avarage price target is $8, with a high forecast of $NaN. The average price target represents a 399.87% change from the last price of $1.6.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Humacyte stock Price Target by analysts
Full breakdown of analysts given Humacyte price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Matt O'Brien Piper Sandler | 50% 1/2 | 11 months ago | $6 274.90% upside | $4.86 | StreetInsider | Previous targets (1) |
Ryan Zimmerman BTIG | 0% 0/1 | 11 months ago | $10 524.84% upside | $4.86 | StreetInsider | Previous targets (0) |
Cowen Cowen Cowen & Co. | 0% 0/1 | almost 3 years ago | $5 212.42% upside | $2.21 | Pulse 2.0 | Previous targets (0) |
Matt O'Brien Piper Sandler | 50% 1/2 | over 3 years ago | $4 149.93% upside | $5.37 | TheFly | Previous targets (1) |
Humacyte Financial Estimates
Humacyte Revenue Estimates
Humacyte EBITDA Estimates
Humacyte Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $1.26M N/A | $1.56M 23.91% | $0 -100% | Avg: $30.14M Low: $17.30M High: $39.34M avg. 0% | Avg: $92.23M Low: $52.95M High: $120.41M avg. 206.01% | Avg: $218.81M Low: $125.62M High: $285.66M avg. 137.24% | Avg: $365.34M Low: $209.75M High: $476.96M avg. 66.96% |
Net Income
% change YoY
| $37.53M N/A | $64.21M 71.08% | $-110.77M -272.49% | Avg: $-98.34M Low: $-100.31M High: $-66.18M avg. 11.22% | Avg: $-49.81M Low: $-63.08M High: $4.13M avg. 49.35% | Avg: $-4.65M Low: $-6.50M High: $-2.07M avg. 90.65% | Avg: $55.84M Low: $24.92M High: $78.02M avg. 1300.00% |
EBITDA
% change YoY
| $-136.98M N/A | $-160.34M -17.05% | $-96.45M 39.84% | Avg: $-18.08M Low: $-23.60M High: $-10.38M avg. 81.25% | Avg: $-55.33M Low: $-72.24M High: $-31.77M avg. -206.01% | Avg: $-131.29M Low: $-171.40M High: $-75.37M avg. -137.24% | Avg: $-219.20M Low: $-286.17M High: $-125.85M avg. -66.96% |
EPS
% change YoY
| $0.94 N/A | $0.62 -34.04% | -$1.07 -272.58% | Avg: -$0.8 Low: -$0.97 High: -$0.64 avg. 25.07% | Avg: -$0.37 Low: -$0.61 High: $0.04 avg. 54.09% | Avg: -$0.05 Low: -$0.06 High: -$0.02 avg. 87.77% | Avg: $0.54 Low: $0.24 High: $0.75 avg. 1300.00% |
Operating Expenses
% change YoY
| $81.20M N/A | $84.57M 4.14% | $23.49M -72.21% | Avg: $259.44M Low: $148.95M High: $338.70M avg. 1004.14% | Avg: $793.92M Low: $455.80M High: $1.03B avg. 206.01% | Avg: $1.88B Low: $1.08B High: $2.45B avg. 137.24% | Avg: $3.14B Low: $1.80B High: $4.10B avg. 66.96% |
FAQ
What is Humacyte stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 362.80% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -100.31M, average is -98.34M and high is -66.18M.
What is Humacyte stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 102.55% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $17.30M, average is $30.14M and high is $39.34M.
What is Humacyte stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 366.73% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$0.97, average is -$0.8 and high is $-0.64.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Humacyte stock. The most successful analyst is Matt O'Brien whose win rate is 50%. He has correctly predicted 1/2 price targets.